{"entity":{"id":"nct03669965","kind":"trial","name":"KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera","aka":[],"tldr":"A phase 2 trial of KRT-232 and Ruxolitinib in myeloproliferative neoplasms, run by Kartos Therapeutics, Inc., active and no longer recruiting.","summary":"KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera is a phase 2 interventional study registered as NCT03669965 by Kartos Therapeutics, Inc., with 20 participants enrolled, started 2019-01-15 and due to reach its primary completion in 2022-04. Interventions recorded: KRT-232 and Ruxolitinib.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03669965","url":"https://clinicaltrials.gov/study/NCT03669965"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":["krt-232","ruxolitinib"],"companies":["kartos-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03669965","phase":"2","setting":"A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera","sponsor":"Kartos Therapeutics, Inc.","enrolled":20,"outcomes":[]},"route":"/trials/nct03669965/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"drug":[{"id":"krt-232","kind":"drug","name":"KRT-232","route":"/drugs/krt-232/"},{"id":"ruxolitinib","kind":"drug","name":"Ruxolitinib","route":"/drugs/ruxolitinib/"}],"company":[{"id":"kartos-therapeutics","kind":"company","name":"Kartos Therapeutics","route":"/companies/kartos-therapeutics/"}]}}